|1.||Rivera, Victor M: 9 articles (05/2013 - 05/2008)|
|2.||Clackson, Tim: 6 articles (05/2013 - 06/2011)|
|3.||Squillace, Rachel M: 5 articles (07/2013 - 06/2011)|
|4.||Berk, Lori: 5 articles (05/2012 - 10/2010)|
|5.||Giles, Francis J: 5 articles (08/2009 - 02/2004)|
|6.||Haluska, Frank G: 4 articles (11/2015 - 01/2012)|
|7.||Mita, Monica M: 4 articles (09/2013 - 04/2009)|
|8.||Miller, David: 4 articles (05/2013 - 06/2011)|
|9.||Wang, Frank: 4 articles (05/2013 - 06/2011)|
|10.||Oza, Amit M: 3 articles (11/2015 - 02/2014)|
01/01/2015 - "In vitro and in vivo models, and a phase I study in which patients with advanced cancer received ridaforolimus (10-40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week) were explored. "
07/01/2013 - "This first-in-pediatrics study shows that the second-generation mTOR inhibitor ridaforolimus is well tolerated in heavily pretreated children with refractory solid tumors. "
07/01/2013 - "A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors."
01/01/2013 - "This open-label, single center phase I study aimed to investigate the pharmacokinetic (PK) and safety profiles of ridaforolimus in Chinese patients with treatment-refractory advanced or relapsed solid tumors. "
01/01/2013 - "A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors."
|2.||Sarcoma (Soft Tissue Sarcoma)
08/01/2012 - "One such mTOR inhibitor, ridaforolimus (AP23573, MK-8669), is currently being evaluated in patients with advanced bone and STS in the ongoing Sarcoma mUlti-Center Clinical Evaluation of the Efficacy of riDaforolimus (SUCCEED) trial."
09/01/2013 - "Phase II and III trials of ridaforolimus have produced promising clinical activity against advanced sarcomas and will be presented. "
07/01/2013 - "This large randomized placebo-controlled phase III trial evaluated the mTOR inhibitor ridaforolimus to assess maintenance of disease control in advanced sarcomas. "
01/01/2012 - "A phase III trial based on these data will further define ridaforolimus activity in sarcomas."
01/01/2012 - "This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas. "
|3.||Renal Cell Carcinoma (Grawitz Tumor)
10/01/2015 - "Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors."
03/01/2011 - "Rapamycin and its analogs temsirolimus, everolimus, and ridaforolimus referred to as "rapalogs" have demonstrated promising efficacy against renal cell carcinoma and are under investigation for the treatment of other malignancies. "
09/01/2006 - "Rapamycin and its analogues, including temsirolimus, everolimus, and AP23573, block the mTOR signaling pathway and induce a cellular state akin to starvation, with significant antitumor activity in a variety of malignancies, including renal cell carcinoma (RCC). "
07/01/2014 - "Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg, advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus). "
|4.||Endometrial Neoplasms (Endometrial Cancer)
11/01/2015 - "Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma."
11/01/2014 - "Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer."
03/19/2013 - "Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial."
11/01/2015 - "Oral ridaforolimus shows encouraging activity in advanced endometrial cancer but is associated with significant toxicity. "
11/01/2014 - "Oral ridaforolimus was reasonably tolerated and demonstrated modest activity in women with recurrent or metastatic endometrial cancers. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
05/01/2008 - "A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. "
05/01/2008 - "Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies."
05/01/2008 - "Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. "
05/01/2008 - "A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies."
07/01/2006 - "Three rapamycin analogs, temsirolimus, everolimus, and AP23573, are in clinical trials for various hematologic malignancies. "
|7.||vorinostat (suberoylanilide hydroxamic acid)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)